Crandall Ryan 4

What Happened

• Ryan Crandall, Chief Commercial Officer of MARIMED (MRMD), had 37,500 restricted stock units (RSUs convert/derivative) vest/convert on May 29, 2026. The filing shows 37,500 shares acquired via conversion (code M) and 12,994 shares withheld/disposed to satisfy tax withholding (code F) at $0.08 per share (total tax withholding reported $1,046). Net shares delivered to Crandall = 37,500 − 12,994 = 24,506 shares. Based on the $0.08 per-share figure in the filing, the net shares are worth roughly $1,960.

Key Details

• Transaction date: 2026-05-29; Form filed: 2026-06-02 (filed within the normal two-business-day reporting window).
• Reported prices: conversion at $0.00 (RSU conversion), tax withholding at $0.08/share; withholding amount reported $1,046.
• Shares involved: 37,500 RSUs converted; 12,994 shares withheld for taxes; net 24,506 shares issued to the insider.
• Shares owned after the transaction: not specified in the provided filing.
• Footnotes: F1/F2—RSUs convert one-for-one into common stock and the issuer withheld shares to satisfy tax withholding. F3—these RSUs were part of a Nov 29, 2024 grant with remaining installments vesting on Nov 29, 2026; May 29, 2027; and Nov 29, 2027.

Context

• This was a vesting/settlement of RSUs (conversion of a derivative), not an open-market purchase or sale. The withholding is a routine tax-cover transaction (cashless withholding) and reflects compensation vesting rather than an active buy/sell decision. Such transactions are common for executive compensation and do not by themselves signal the insider’s market view.